Spiral Therapeutics (www.spiraltx.com) is a clinical-stage company focused on the development of first-in-class therapies targeting inner ear disorders. Spiral’s lead candidate LPT99 for prevention of hearing loss is expected to reach clinical stage in early 2018. LPT99 is a small molecule with strong anti-apoptotic activity, administered transtympanically in a hydrogel formulation to effectively reach the hair cells in the inner ear. LPT99 has shown strong signs of safety and efficacy in animal models of prevention of chemotherapy-induced hearing loss and is currently being tested for the treatment of other hearing loss indications, including noise-induced hearing loss and age-related hearing loss. Spiral is headquartered in San Francisco, CA and has offices in Baltimore, Maryland and Barcelona, Spain.